International Edition
Latest News
Health

AI Detects Missed Pancreatic Tumors; FDA Approves First KRAS-Targeted Drug

Artificial intelligence detected early pancreatic tumors on CT scans that radiologists had missed years earlier, Mayo Clinic researchers found, while the FDA approved the first RAS-targeted therapy for the disease this year. The developments arrive against a stubborn…

Artificial intelligence detected early pancreatic tumors on CT scans that radiologists had missed years earlier, Mayo Clinic researchers found, while the FDA approved the first RAS-targeted therapy for the disease this year.

The developments arrive against a stubborn backdrop: about 67,000 people in the United States are diagnosed annually and the five-year survival rate remains 13 percent. Most patients learn they have the disease only after it has spread, when surgery is no longer an option.

“By the time symptoms develop, it’s already progressed in the majority of patients,” Dr. Mark Truty, a cancer surgeon at Mayo Clinic, told MPR News.

AI spots tumors on old scans

Mayo Clinic researchers reviewed abdominal CT scans that patients had received for unrelated reasons years before a pancreatic-cancer diagnosis. The original reads showed no cancer. When the same images were analyzed with an AI model trained to examine individual pixels, the system identified tumors that were too small or subtle for human detection, Truty told MPR News.

Mayo has moved the finding into a clinical trial enrolling people at elevated risk for pancreatic cancer. The trial uses the AI tool to search routine CT scans for early, treatable tumors.

AI Detects Missed Pancreatic Tumors; FDA Approves First KRAS-Targeted Drug
Photo: Hospital Clínic Barcelona

FDA approves first KRAS G12D inhibitor

In 2024 the Food and Drug Administration approved daraxonrasib, marketed as Rasonque, for pancreatic cancer harboring a KRAS G12D mutation. The mutation helps drive tumor growth and spread in a subset of patients.

Bob Myers, who has lived with the disease for three years, started the drug about a month ago and said his tumors appear to be shrinking. “There’s a lot of ups and downs when you have a disease like this. I’m fortunate to be here almost three years now, and I’m counting on being here for longer,” Myers told MPR News.

RAS inhibitors tested after surgery

Hospital Clínic Barcelona, a designated European reference center for pancreatic cancer, is recruiting patients for the RASolute 304 trial, which evaluates daraxonrasib as adjuvant treatment — given after surgery to reduce the risk of relapse. Data presented at the ASCO annual meeting in June showed the drug doubled survival in metastatic patients receiving it as a later line of therapy, the hospital reported.

“Until now we had encouraging data for this drug as second-line treatment in metastatic disease, where we saw survival double in these patients, in the trial presented at the ASCO congress this past June,” the center stated.

Complex surgery expands operable cases

Advances in vascular resection and reconstruction — removing and rebuilding involved veins and arteries — now allow surgery for tumors once deemed unresectable. Hospital Clínic Barcelona performed 50 pancreatic resections by mid-October 2026, a pace the center attributes to its multidisciplinary model and CSUR referral pathway.

“We want to encourage everyone in a similar situation not to give up. Getting informed, asking for a second assessment and exploring all the available options can make a big difference,” the hospital said.

Advocacy fuels research pipeline

Patient advocates have sustained funding pressure. Kym Jolstead launched Kathie’s Coffee in 2021 after her mother’s death, directing a portion of proceeds to the Pancreatic Cancer Action Network. Sarah Taylor, a health-care worker whose father died less than two months after his diagnosis, joined the Minnesota chapter of the same organization to raise money and awareness.

“I knew that my mom wouldn’t benefit from it,” Jolstead said of the new treatments. “But I know that one day it will make a difference.”

Hospital Clínic Barcelona, founded in 1906 and opened on December 22 of that year with a capacity of 400 patients, serves as the university hospital for the University of Barcelona Faculty of Medicine.

Its research activity is centralized through the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and it manages the Foundation for Biomedical Research (FCRB). In 2020 Newsweek ranked it the best hospital in Spain and among the 25 best worldwide, and it has been recognized by IASIST as a top 20 hospital in Spain for 10 consecutive years.

Mayo Clinic’s AI screening trial continues enrolling high-risk participants. The RASolute 304 adjuvant trial is recruiting in Barcelona. Both aim to determine whether earlier detection and mutation-targeted therapy after surgery can push survival past the incremental gains of the last decade.

About the author: Health Desk

Health Desk at Archynewsy.